Aagami, Inc., is a life sciences consulting firm offering, · Technology Licensing · Strategic Consulting · Market Intelligence For Global companies in · Technology Licensing Office of Universities · Medical Devices & Technology · Pharma · Biotech · Consumer Healthcare · CROs, CDMOs In Brief, Aagami Brings: · Deep Experience of overcoming business and socio-cultural differences of various countries · Extensive ‘C’ level network nurtured for over 15 years · Global Deal making skills, honed for decades · Partners having combined experience of 250+ years · Supplementing your bandwidth to save time, effort & cost 75+ Bio Pharma clients globally across 125+ assignments have put their trust in Aagami since 2003.

1. Technology Licensing
→ Realizing Possibilities, Together ←
2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
January 2019

2. A life sciences consulting firm offering
For Global companies in
Aagami, Inc.
Strategic Consulting
Technology
Licensing
Market Intelligence
IP office of
Universities
Pharma Biotech
Medical
Devices
Consumer
Healthcare
2

3. Aagami
Offerings
In-/Out-
Licensing
Partnership/
Co-
Development
Funding/
Investment
Mergers &
Acquisitions
Market Entry
Market
Development
Strategy
Finding the
Right Partners
Your Needs, we Serve
• JV and/or Distributors
• Contract Sales/Marketing
• Contract Manufacturing,
• CRO and CRAMS providers
3

4. Our Understanding of Tech Transfer Offices Needs
Realistic Evaluation of
commercial potential
Reach in the Investors’
world
Access to Global
Commercial Network
Ability to speak
“Investors’ language”
Commercial Perspective
on
Technology
‘Out of box’ thinking
to widen
market applications
Ability to talk multi
cultural, multi
geographical
“Business’ language”
4

5. Aagami brings,
Value
Proposition
Deep Experience
of overcoming
business and
socio-cultural
differences of
various countries
Extensive ‘C’ level
network nurtured
for over 15 years
Global Deal
making skills,
honed for decades
Partners having
combined
experience of
250+ years
Supplementing
your bandwidth to
save time, effort &
cost
USP
5

6. Aagami, Technology Licensing Services
Consolidate
Industry
demand
Consolidate
available
technologies
Evaluate
Technologies
to fit the
demand
Evaluate
Commercial
Potential
Promote selected
technologies
•Generate focused marketing
brochures
•Broadcast to specific
(relevant) companies
•Exchange information with
the interested
•Help and support finalizing
Licensing agreements
6

7. 7
Sample list of Clients whom we have served
USA
OncBioMune with license from
Louisiana State University LA
Loyola Univ. Chicago IL
DesignMedix with license from
Portland State University OR
University of Messina, Italy Spinoff
CREAGRI® CA
Impel NeuroPharma with license
from University of Washington WA
UT Austin Spinoff DisperSol TX
MacuCLEAR, with license from
Texas A&M University Spinoff TX
International
Univ. Of Bergen Spinoff UTR Norway
Toppan KK, with technology from
RIKEN Japan
Opsona, a spin-out from Trinity
College Dublin Ireland
University of Otago, Dunedin
New
Zealand
Pieris AG, with license from
Technische Universität München
Germany
Recife University based Nanosensing Brazil
Monash Univ. based Phosphagenics Australia
Aagami has completed over 125 assignments for more than 75 clients since 2003

8. 8
Strategy
Segment
IN Licensing
OUT
Licensing
M & A
Partnership
Co-Development
Regulatory
Market
Research
& Entry
Supply Chain &
Distribution
BD
Pharmaceuticals
Biotechnology
Delivery Technology
Diagnostics
CRO & CRAMS
Consumer Health Products
Nutraceuticals/
Cosmeceuticals
Medical Device
Labware
Supported all Segments and Strategies
The colored boxes represent our experience in that Sector and assignment completed in Strategic area

9. Our Proven Approach
Setup
• Understand and capture
important details about your
asset/technology
• Prepare ‘Elevator Pitch
(EP)/Teaser’ customized to
specific business culture
• Identify relevant companies and
the right persons from our
database and resources
Prospect
• Broadcast EP/Teaser to identified
Relevant Companies
• Follow-up with phone calls and
emails
• Coordinate CDAs with interested
Companies
• Supply further info through
emails
• Organize conference calls for
clarifications
Finalize
• Organize Road show
• Manage appointments with right
executives
• Coordinate the logistics of the
road show
• Advise on structuring the deal
• Support in negotiations (most
critical)
All these steps require ~80 hours of effort every month per geography
9

10. 10
Engagement Model
• After 6 months you can
choose to continue based on
progress
• This brings skin in the game of
both parties
• One-time success fee
payment option also
available
• We get our profits only
from Success Bonus
• A senior Consultant, mid-level
consultant, Analyst team
deployed
• Work with focus on your
success as that gives us our
success
Monthly Commitment Fee + Success Fee
Dedicated
Teamwork
Success bonus
Small Monthly
‘Commitment’
Fee
~80 hours/month/geography A small % of value received by
you
for at least 6 months

11. 11
Dinesh Jain, MBA – Founder CEO
• A business leader in Science and technology industry since 1984 with global experience in starting and
managing several technology companies. Has held positions of CEO, President, Vice President, Country
Manager. Executed several dozen international deals across 4 continents. He is a regular speaker in
International conferences on Life Sciences Business and is also on board of several consulting and research
companies.
Dr. Mahendra Shah, Ph D – Scientific & Business Advisor
• A veteran Scientific and Business leader in Bio-Pharmaceutical field for several decades. After his PhD from NY,
worked with some of the top-notch companies like Bristol, Squibb, Schering, Lyphomed, Fujisawa, EJ Financials,
First Horizon, NextWave. Mahendra is an active Investor in BioPharmaceutical field and is on the Board of
several Biotech and Pharma companies.
Michael S. Rosen, MBA - Business
• A Senior executive and entrepreneur working globally since 1974. Managed 3 multinational pharma and agro-
science companies working in Europe, Latin America, Japan, Canada, Asia and Israel. CEO experience starting
and growing several biotech and medical device companies in the U.S. and Europe, raising more than $50
million in equity and taking a company public. Economic development expertise creating and expanding vibrant
science parks and life-science ecosystems as public-private partnerships.
Aagami Leadership Team 1 of 3

12. 12
Aagami Leadership Team 2 of 3
Dr. Shridhar Andurkar, Ph D – Scientific
• Chair and Associate Professor of Pharmaceutical sciences at Midwestern University, Chicago College of
Pharmacy, is a Ph D from Auburn University in Medicinal Chemistry, Conducted postdoctoral research at the
University of Houston.
• Dr. Andurkar has published numerous papers and made several presentations in this field. He holds a US patent
in the area of anticonvulsant drugs and is on the advisory boards of several companies.
Dr. Aman Ahuja, M.D., F.P.M., F.R.C.A. – Medical
• A specialist pain medicine physician and consultant at the North Queensland, Australia.
• MD Anaesthesia from India, Fellow of Royal College of Anaesthetists, Ireland, Masters in Pain Medicine from UK,
Fellow of Tess Cramond Multidisciplinary Pain Centre, Australia.
• Dr. Ahuja has focus on clinical practice, research and advancing rational therapies for a diverse range of
conditions.
• His current interests include studying the expanding role of radiofrequency in field of Pain Medicine. Dr. Ahuja
uses a compassionate and multidisciplinary approach in his well-known practice as a Pain Specialist and
Anesthetist.

13. 13
Nancy Chew – Regulatory
• A serial entrepreneur, veteran business leader, biochemist and Pharmacologist by education
• Nancy’s decades of experience encompass nearly every aspect of regulatory affairs including Strategic Planning,
FDA Liaison, Submissions and Compliance.
• Several top honors & award winner and Advisor to numerous Life Sciences companies.
• Nancy's accomplishments and achievements of working since 1979 would take several pages to detail.
Godwyn Francis – Vice President
• Since 2000 Godwyn has been working with companies like Accenture, Prudential, Tata and other firms in
management consulting.
• At Aagami, Godwyn leads business development and Strategic growth efforts. He provides key support and
oversight to research and consulting assignments for global clients.
• He has worked on multiple term sheets each year and contributed to signing deals worth tens of millions of
dollars.
• His work includes regular engagement with top management of life sciences companies globally.
Aagami Leadership Team 3 of 3

14. In Summary – Aagami, Inc.
Multi-
geographic
presence
Large ‘C’
level
network
20+ deals
75+ Clients
125+
Assignments
Client
Success –
most
important
250+yrs
Global
Experience
Shridhar Andurkar
Nancy Chew
Dinesh Jain
Michael Rosen
US$ 500+MM
X-Border deals
and Investments
14

15. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Facilitating investment for development of targeted therapies
and therapeutic vaccines
• Investments and partnering to further develop its
technologies and pipeline.
15
Louisiana State University spinoff, commercializing University laboratory-developed technologies
• Aagami scanned the global market, identified right investors/
partners, and took them to 50 + companies.
• With focused efforts 10+ companies had post CDA level
scientific and clinical discussions.
• Aagami kept facilitating and persevering, 3 companies
moved to term sheet level discussions.
• Finally Aagami found a right partner to facilitate reverse
merger with a OTC Markets listed company.
• This is enabling access to large sums of funds to develop
clinical stage programs.
• Listing on OTC Markets by a reverse merger
• Financial resources to enable development of existing
pipeline and technologies

16. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Exclusive Worldwide Licensing for a Fragrance and Flavors
Technology
• The University developed an improved process to make Safranal
faster, cheaper, and greener.
• After patenting it they were finding it difficult to out license it
even after more than 2 years of trying .
16
Technology Licensing Office of a reputed University from Chicago area
• Aagami deployed a senior consultant to understand and capture
important details about the asset / technology
• Identified relevant companies in India and elsewhere.
• Shortlisted 68 companies and sent them customized ‘Elevator
Pitch’ (EP)
• After several follow ups on phone calls and emails, coordinated
CDAs and conference calls with several interested Companies and
brought 3 companies on term sheet level discussions
• Aagami supported in structuring and negotiating the deal
discussions.
• Finally established the partnership within 6 months from the start
date
• Technology licensing partnerships made with 2
companies in India in 6 months
• Client said: “It takes a lot of time and people to
pull off an agreement like this, ….. we’re very
pleased that we were able to align ourselves
with these two reputable international
companies.”
http://loyolastudentdispatch.com/2010/11/05/loy
ola-flavor-and-fragrance-research-goes-global/
Lifesciences Catalyst

17. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Establishing Partnerships for Development and
Commercialisation of Novel Class of Protein Drugs
• Innovator partners in India to collaborate on a new class of
proteins - Anticalins® to develop various programs in
Oncology and Ophthalmology.
17
Technical University of Munich spinoff Biotech company making safer, differentiated Novel drugs
• Aagami identified right partners, and took them to 7
interested companies for Anticalins®
• With focused efforts 3 companies moved to term sheet level
discussions. Aagami kept facilitating and persevering. 2
companies remained for final negotiations.
• Aagami maintained its spirits and perseverance knowing
Indian ways of working; even when client was ready to give
up as per Western ways.
• Finally co development partnership happened in next few
months with one company in Oncology.
• Second company took more time and couple of visits before
signing co-development deal for ophthalmic therapy.
• Client signed co-development deals with 2 companies in Oct
and Dec 2013 respectively
• Right companies, right advice, structure, perseverance and
commitment were the key success factor. in making it
happen.
• Aagami proved highly influential in negotiations for
finalization of the deals due to deep experience in business
culture nuances of India.
• It brought repeat and referral business to Aagami.

18. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Study of Market Potential and Prospective Partners in India for
hand-held qPCR Diagnostic Device
• Innovation center wanted to study the market potential in India for their innovative
mobile, lightweight molecular diagnostic technology and device.
• On Aagami’s suggestion, client agreed to include regulatory overview and potential
partners in the study.
18
Innovation Center of a New Zealand University focused on Health Sciences
• Aagami involved a team of a senior and a junior researcher to
conduct secondary and primary research to assess and collect
market data.
• Identified Competitors and their product ranges and also did a
brief comparison analysis.
• Prepared a crisp and concise report with data, analysis and
recommendations
• Also prepared a regulatory overview document
• Captured the potential end users of the product as well as
shortlisted potential partners
• Offered consulting support for Partnership Development and India
Market Entry with a clearly defined Partnering Strategy and
roadmap to achieve the goal.
• The report helped the University in determining
conclusively on India market initiative.
• Pleased with the report, the University
appointed Aagami to find a licensing partner in
India

19. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Global NPV of Technology (in USD Million)
(P) Pessimistic Scenario
Discount rate 8.60%
Year 2012 2013 2014 2015 2016 2017 2018
Time 0 1 2 3 4 5 6
Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93
Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19
Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98
Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57
Commercialisation Costs 400.00 - - - - - -
Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11
Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55
Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56
Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61
Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44
NPV 1,524.77
Assessment of Global Net Present Value (NPV) of a revolutionary
Nanotechnology Based Diagnostic Platform
• Client wanted to commercialize ground breaking technology in the
MI Diagnostics field, and wanted to know its commercial potential
so that suitable licensing fees and model could be determined and
also value could be showcased to Licensees
19
US Investors Controlled Innovation lab from Recife University, Brazil
• Aagami involved a team of a senior consultant part time and a
business analyst full time to conduct primary and secondary
research involving domain specialists to capture current market
scenario.
• Performed competitive benchmarking to assess a Relative Cost
Benefit Index used later for determining technology platform
(product) pricing.
• Projected annual demand for next ten years in three different
scenarios - Median, Optimistic and Pessimistic across multiple
disease categories.
• Forecasted Global Average Selling Price (ASP) and Cost associated
with capex and opex
• Validated commercializing options and measured incremental
financial scenario for potential licensees
• Determined the Global Net Present Value (NPV) and created
Financial models
• NPV of the technology and indicative licensing fees, along with
several insights generated, served as conclusive guidance to the
client for deal-making and negotiations.
• The client was delighted which also resulted in repeat assignments
such as Commercialization Support.

20. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Assessment of NPV of a Patented Anti-Malarial Drug which
Overcomes Microbial Resistance
• A Novel Therapeutics discovery company with focus on anti-
malarial had discovered a Hybrid drug using innovative reversal
agent for drug resistance.
20
Portland State University, US based Novel Therapeutics company focused on drug resistant diseases
• Aagami engaged domain specialists for the client need.
• The malaria market was studied and three different annual demand
scenarios -Pessimistic, Median and Optimistic was projected for 10
years since drug introduction in the market.
• Research on current malaria treatment and available drugs was
conducted to build competitive mapping. Along with inputs from
industry experts, dosage, price and market share data across
competitive drug types was used to build COGS and overall cost
estimates. Value based pricing was also estimated with merits of R&D
Tax Credits were incorporated in the model.
• Using previous drug introductions, and the competitiveness of the drug,
the uptake and adoption rate for the new drug was calculated.
• Finally the Global Net Present Value (NPV) of the client Hybrid drug
(including technology) was done to calculate the indicative license fees
under various scenarios.
• Comprehensive spreadsheet based automated tool with sensitivity
analysis to change inputs and build multiple case scenarios.
• NPV of the drug and indicative licensing fees, along with several
insights generated, served as conclusive guidance to the client for
deal-making and negotiations.
• The client was impressed by the quality of the deliverable and
particularly appreciated the sound, research backed assumptions
and projections.
Lifesciences Catalyst
Market Sizing - Global Anti-Malarial Drug
Safety Stock 15.0%
2000 2001 2002 2003 2004
P
Lower
( In millions)
151 153 152 156 158
M
World Level
( In millions)
226 229 231 236 240
O
Upper
( In millions)
304 307 312 319 325
P 151 153 152 156 158
M 226 229 231 236 240
O 304 307 312 319 325
Malaria Cases (Number
of Cases (95%
confidence interval)
Malaria cases adjusted
for Safety stock etc

21. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Technology Out-licensing of Transdermal Drug Delivery Technology
with 3 Indian Companies | 4 deals
q To Out-License TPM® Technology and Co-Develop in clinic
products using proprietary Delivery technology and market
such products in India and possibly larger region.
21
TPM® Technology and Products Company from Australia
q Aagami scanned numerous companies and got 10 relevant
companies interested.
q Discussion with 8 companies progressed.
q Took client to India 3 times for term sheet level meetings
and deal signing.
q Facilitated entire evaluation and deal structuring process
q Aagami made sure testing and other protocols were
honoured before deal was made.
q During the process Aagami ensured clear understanding
despite socio cultural differences in styles of working.
q 4 Deals with 3 global companies of India; One Global deal,
One 14 geography deal, other regional deals
–The first deal was struck for diclofenac topical gel formulation
containing TPM platform. The Indian partner not only launched
their own product but also out licensed to a major western pharma.
–The second alliance was struck for use in Skin Whitening and under
eye cream.
–Third deal - Aagami was able to facilitate a new business model
with this prospect, who using client technology increased bio
availability as well as stability of a specific antibiotic.

22. Aagami, Inc.
2135 City Gate Lane Suite 300
Naperville, IL 60653, USA
+1-630-364-1837
Business Development
Godwyn Francis, Vice President
godwyn@aagami.com
+1 630-909-3341
www.aagami.com
Connect with us
22